Today, the U.S. Senate released its version of the health care reform bill, titled the Better Care Reconciliation Act, and in response, the Cystic Fibrosis Foundation affirmed its opposition to the legislation.
Site Search
Two Phase 3 clinical trials of tezacaftor (VX-661) in combination with ivacaftor (Kalydeco®) showed positive results, Vertex Pharmaceuticals announced today.
New data show positive results in individuals with a single F508del mutation as well as people with two copies of F508del and support continued development of triple combination therapies.
The Cystic Fibrosis Foundation's Greater New York Chapter recently recognized leading journalist Scott Pelley at the 14th annual Breath of Life Gala for his unwavering dedication to those living with CF.
The Institute for Clinical and Economic Review (ICER) is developing an assessment of the clinical effectiveness and value of lumacaftor/ivacaftor (Orkambi®) and ivacaftor/tezacaftor (VX-661). The Foundation is sharing input throughout the process to help incorporate the patient and clinical perspective.
We have about 70 chapters and offices across the country that work diligently to raise funds and support our community in the search for a cure. They host events (including virtually and outdoors) and serve as a hub for the CF community. Get to know them!
The U.S. House of Representatives has passed the American Health Care Act (AHCA), legislation that fails to adequately protect people living with cystic fibrosis.
The Cystic Fibrosis Foundation presented four individuals with awards at the 2018 Volunteer Leadership Conference (VLC). The awards given were the Tomorrow's Leader Award, the Jena Award, the Alex Award, and the Dream Big Award.
The Patient Registry is an invaluable tool for researchers conducting observational studies about people with CF in the U.S. About 50,000 individuals have been followed in the Registry since its inception in 1986; many of them have been included for over 20 years.